Reviewing Lunai Bioworks (NASDAQ:LNAI) & Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB) and Lunai Bioworks (NASDAQ:LNAI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Valuation & Earnings

This table compares Genmab A/S and Lunai Bioworks”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$4.30 billion	7.61	$963.00 million	$1.17	44.80
Lunai Bioworks	$51,992.00	15.96	-$3.56 million	($0.40)	-0.41

Genmab A/S has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Genmab A/S has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Genmab A/S and Lunai Bioworks, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0	1	10	1	3.00
Lunai Bioworks	1	0	0	0	1.00

Genmab A/S currently has a consensus target price of $53.61, suggesting a potential upside of 2.28%. Given Genmab A/S’s stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Lunai Bioworks.

Insider and Institutional Ownership

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genmab A/S and Lunai Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genmab A/S	16.97%	13.67%	6.42%
Lunai Bioworks	N/A	N/A	-42.62%

Summary

Genmab A/S beats Lunai Bioworks on 13 of the 15 factors compared between the two stocks.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.